Randy is a Senior Advisor on the Life Sciences team, with over 35 years of experience as an endocrinologist, chief medical officer, and drug development executive.
Randy joined Frazier in 2007 as a Senior Advisor to the Life Sciences team. He is closely involved with the Life Sciences team’s sourcing and evaluation of new opportunities, and he has been involved with several portfolio companies to assist with clinical trial design and execution, regulatory strategy, and other development-related activities. Randy currently serves on the board at Millendo Therapeutics (NASDAQ: MLND), and previously was a board member of Marcadia Biotech (acquired by Roche).
Previously, Randy was a co-founder and Chief Medical Officer of QuatRx, a pharmaceutical company backed by Frazier focusing on compounds in the endocrine and metabolic therapeutic areas. Earlier he served in various management positions at Parke-Davis, the pharmaceutical division of Warner-Lambert, including VP for Clinical Research and Drug Development. After Pfizer acquired Warner Lambert, Randy was VP of Global Project Management for Pfizer. Throughout his time in the pharmaceutical industry, Randy has been involved in the development and approval of several drugs including: Lipitor, Rezulin, FemHRT, Estrostep, and Osphena. Prior to his tenure at Parke-Davis, he was on the faculty of the Harvard Medical School and an attending physician at Massachusetts General Hospital.
Randy received his M.D. from the University of Kansas, where he did clinical training in internal medicine and endocrinology followed by a research fellowship at N.I.H. He earned a B.A. in Biology and Chemistry from Tabor College. Randy has authored multiple scientific publications and is a member of numerous scientific and clinical organizations.
University of Kansas (M.D.)